《大行報告》高盛維持比亞迪(01211.HK)「買入」評級 年底價格競爭已反映
高盛發表評級報告,相信市場對持續的價格戰已有共識,料比亞迪(01211.HK)第四季平均售價下跌3%;踏入第四季,該行預料比亞迪品牌繼續高端化及出口增長,將會帶動混合平均售價;鋰價進一步下跌和規模經濟,將推動毛利率擴張和公司單位利潤的增加。
對於明年而言,該行預料市場競爭持續,新進行業人士或推出新車型,而大多數OEM廠商優先考慮銷售量而非盈利能力。該行相信,OEM廠商如比亞迪,擁有規模優勢、正利潤率、健康的資產負債表和強勁的現金流,將處於更強的競爭位置,並成為最終贏家。
該行表示,比亞迪現價已將年底價格競爭反映出來,維持其「買入」評級,目標價為346元。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.